FACT News

NEWS RELEASE
Issued: April 13, 2022
Contact: Linda Miller

OMAHA, Neb. – King Abdulaziz Medical City – Riyadh, Saudi Arabia received internationally recognized accreditation by the Foundation for the Accreditation of Cellular Therapy (FACT). Directed by Mohsen Alzahrani, MD, it is the first and only cellular therapy program in Saudi Arabia to be recognized by FACT. The program received accreditation on July 1, 2022, and is accredited for Adult and Pediatric Allogeneic and Autologous Hematopoietic Progenitor Cell Trans-plantation, Marrow and Peripheral Blood Cellular Therapy Product Collection, and Cellular Therapy Product Processing.
Read full news release

NEWS RELEASE
Issued: April 13, 2022
Contact: Linda Miller

OMAHA, Neb. — Foundation for the Accreditation of Cellular Therapy (FACT), the leader in voluntary inspection and accreditation in the field of transplantation and cellular therapy, announces its new website and branding launch.
Read full news release

NEWS RELEASE
Issued: October 25, 2021
Contact: Linda Miller

OMAHA, Neb. — FACT is pleased to announce the first step in efforts to transition to an enhanced website with the establishment of a new email domain and phone numbers.
Read full news release

The draft third edition FACT Common Standards are available for review and comment through October 1, 2021.
Read the draft Standards, Summary of Changes, and instructions for submitting comments.

The eighth Edition FACT-JACIE International Standards for Hematopoietic Cellular Therapy Product Collection, Processing, and Administration and its accompanying eighth edition Hematopoietic Cellular Therapy Accreditation Manual have been officially published.

The objective of the FACT-JACIE Standards is to promote quality medical and laboratory practice in hematopoietic progenitor cell transplantation and therapies using hematopoietic derived cellular products. FACT-JACIE Standards are unique in depth and breadth, being applicable to all phases of cell collection, processing, storage, transportation, and administration, and to all phases of clinical application including standard of care therapies and products, products administered under regulatory-approved clinical trials, and licensed (or other regulatory approval) products.

The scope of the Standards includes hematopoietic progenitor cells (HPCs), nucleated cells or mononuclear cells from any hematopoietic tissue source collected for therapeutic use other than as HPCs, immune effector cells (IECs), and genetically modified cells.

The eighth edition Standards become effective on August 16, 2021. All organizations accredited under these Standards are expected to be in compliance with the requirements by that date. Although there may be a few inspections remaining to be completed under the previous edition due to COVID 19-related delays, all other inspections scheduled after this date will be under the eighth edition.

Review the Summary of Changes for the eighth edition FACT-JACIE Standards
Download the eighth edition FACT-JACIE Standards for free
Download the eighth edition Hematopoietic Cellular Therapy Accreditation Manual for free
Purchase printed copies of the eighth edition FACT-JACIE Standards
Purchase printed copies of the eighth edition Hematopoietic Cellular Therapy Accreditation Manual
Download additional supporting documents

NEWS RELEASE
Issued: October 25, 2021
Contact: Linda Miller

OMAHA, Neb. — The Foundation for the Accreditation of Cellular Therapy (FACT) is pursuing an opportunity to establish independent operational functions by the end of 2021 thus ending the 25-year collaborative relationship with the University of Nebraska. Read full release

To assist entities with determining ISBT 128 registration fees, ICCBBA created a registration license fee flyer.
View the flyer.

In October and November 2020, 11 entities received accreditation from the Foundation for the Accreditation of Cellular Therapy. For a complete list of programs achieving accreditation, review the full accreditation report.